pEEVGmCSF-b7.1

pEEVGmCSF-b7.1 is a non-viral therapeutic DNA plasmid encoding both **granulocyte-macrophage colony-stimulating factor (GM-CSF)** and the costimulatory immune molecule **B7-1 (CD80)**, designed for **electroimmunogene therapy** of solid tumors. The therapy works by electroporation—a technique using electrical pulses to facilitate plasmid entry into tumor cells—leading to local expression of GM-CSF and B7-1 at the tumor site. GM-CSF promotes recruitment and activation of antigen-presenting cells like dendritic cells and macrophages, while B7-1 acts as a costimulatory signal enhancing T cell activation. Preclinical studies showed that intratumoral electroporation of pEEVGmCSF-b7.1 induces potent, durable antitumor immune responses, resulting in complete regression of established tumors in significant proportions of treated mice (66% in CT26 colorectal cancer model, 100% in B16F10 melanoma model). The treatment significantly increases tissue levels of proinflammatory cytokines (interferon-γ, interleukin-12), enhances populations of cytotoxic and IFN-γ-producing NK cells, and elevates IL-12-expressing B cells, while decreasing T-regulatory populations and levels of anti-inflammatory cytokine IL-10. Survivors develop tumor-specific immune memory and protection against rechallenge[2][5]. Developer information is not directly stated but research was conducted by oncology research groups in university settings[2][5].

Other names

pEEVGmCSF-b7.1pEEVGmCSF-b-7.1pEEVGmCSF-b 7.1